Lee Ainslie Esperion Therapeutics, Inc. Transaction History

Maverick Capital LTD

  • $5.17 Billion
  • Q4 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022
SELL
$4.81 - $11.92 $240,370 - $595,678
-49,973 Closed
0 $0
Q3 2021

Nov 15, 2021
BUY
$11.34 - $21.37 $56,484 - $106,443
4,981 Added 11.07%
49,973 $602,000
Q2 2021

Aug 16, 2021
BUY
$19.4 - $28.71 $872,844 - $1.29 Million
44,992 New
44,992 $952,000

Others Institutions Holding ESPR

# of Institutions
215
Shares Held
129M
Call Options Held
1.78M
Put Options Held
1.27M
View Full List

About Esperion Therapeutics, Inc.

ESPR Quotes by TradingView
  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $123M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track Lee Ainslie's Portfolio

Track Lee Ainslie Portfolio

Follow Lee Ainslie (Maverick Capital LTD) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

News

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email